Valeant Announces Third-Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Valeant Pharma (VRX) Trades Near High, Up 18%
November 7, 2017 9:44 AM ESTValeant Pharma (NYSE: VRX) Trades Near High, Up 18%
... MoreValeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views
November 7, 2017 7:10 AM ESTValeant Pharma (NYSE: VRX) reported Q3 GAAP EPS of $3.69, versus ($3.49) last year. Revenue for the quarter came in at $2.22 billion, versus $2.48 billion reported last year and the consensus of $2.165 billion. Adjusted EBITDA (non-GAAP) of $951 million, versus the consensus of $872 million and adjusted Net Income of $367 million versus the consensus of $311 million.
"Our strong third-quarter performance... More
